In Wednesday’s show, we look at a new cancer drug, Avastin, which can reportedly extend patients’ lives. So just how much medical care should be made available to patients at the end of their lives?
Henry Aaron, a senior fellow and noted health care expert with the Brookings Institution in Washington DC, joins Martin Savidge to discuss the issue.
Tell Us What You Think:
In an effort to bring down healthcare costs, should the U.S. government limit payment for cancer-fighting drugs that only extend life by a few months?
Please remember to be respectful and on-point in your comments. Malicious or offensive comments will be deleted and repeat offenders will be banned.